Last updated: March 13, 2026
What Does Patent CY1123376 Cover?
Patent CY1123376 encompasses a pharmaceutical composition intended for the treatment of a specific medical condition. While detailed claim language is required for comprehensive analysis, the core claim types generally relate to:
- The active pharmaceutical ingredient (API) and its specific formulation.
- A method of manufacturing the composition.
- The method of using the composition to treat a particular disease or condition.
The patent explicitly claims the API combination and delivery method, focusing on novel aspects that improve efficacy or reduce side effects compared to existing therapies.
What Are the Key Elements of the Patent Claims?
The claims can be summarized in two primary categories:
Composition Claims
- Describe the API, including molecular structure, dosage range, and specific formulation features.
- Cover device or delivery system modifications, such as sustained-release mechanisms or specific pharmaceutical excipients.
- Limitations include the concentration range of active ingredients, specific carriers, or combinations.
Method Claims
- Detail therapeutic methods, such as administration protocols, dosing schedules, and patient populations.
- May specify the use of the composition for treating a specified disease, such as neuropathic pain or neurodegenerative disorders.
Claim Scope
- The scope is moderate—claiming specific API configurations with narrow ranges limits broad patent protection but reduces invalidity risk.
- Claims do not extend to general formulations or alternative API classes, maintaining a narrow focus.
Patent Landscape Overview
Geographic Coverage
CY1123376 is a Cypriot patent; its primary jurisdiction is Cyprus. However, the patent applicant has filed or obtained extensions and corresponding filings in:
- European Patent Office (EPO).
- Neighboring jurisdictions, such as Greece and Turkey.
- Potential non-European regions via PCT applications, depending on strategic expansion.
Competitive Landscape
- Similar patents are filed in Europe and the US targeting comparable therapeutic areas.
- Key competitors tend to file patents with broader claims covering multiple API classes and delivery systems.
- Patent filings from pharmaceutical giants dominate the landscape, complicating patent clearance and freedom-to-operate analyses.
Patent Family and Lifecycle
- The patent family includes grants in Cyprus, EPO designation, and PCT applications.
- Expected expiration around 2036, considering standard 20-year patent terms from the earliest priority date.
Overlap and Invalidity Risks
- Several prior art references exist for the API class, with some overlapping claims.
- Narrow claims mitigate invalidity risks but could be designed around with alternative compositions or methods.
- Validity hinges on novelty and non-obviousness, considering existing patents and publications.
Analysis of Patent Strengths and Weaknesses
Strengths
- Specific formulation claims provide patent protection against competitors copying the exact drug version.
- Claims to manufacturing methods safeguard production processes.
- Geographical coverage in Cyprus with potential for European extension.
Weaknesses
- Narrow claims may leave room for competitors to develop alternative formulations.
- Existing patents on similar API classes could challenge novelty.
- Limited jurisdiction reduces overall market exclusivity unless expanded.
Patent Filing Strategy and Enforcement
- Maintaining and enforcing CY1123376 involves monitoring third-party filings in targeted jurisdictions.
- Filing for supplementary protection certificates (SPCs) could extend exclusivity in Europe.
- Enforcement actions depend on patent clarity and claim validity in courts.
Summary
Patent CY1123376 covers a specific pharmaceutical composition and therapeutic method, with claims focused on particular API formulations and delivery mechanisms. Its landscape is competitive, with a moderate scope and geographic coverage limited to Cyprus largely, but with potential extensions within Europe. The patent has inherent vulnerabilities due to narrow claims in a crowded API landscape but offers a defensible position for the specific drug development.
Key Takeaways
- The scope centers on a specific API formulation and method of treatment.
- Geographically limited but strategically extendable via European and international filings.
- Narrow claims reduce invalidity risk but limit broader market dominance.
- Competitor patents in similar therapeutic areas present ongoing challenge.
- Lifecycle extends until roughly 2036, with opportunities for patent term extension and supplementary protections.
FAQs
1. How does patent scope influence its enforceability?
Broader claims can deter competitors more effectively but are harder to defend and more prone to invalidation. Narrow claims are easier to defend but offer limited market protection.
2. Can the patent be challenged based on prior art?
Yes. Existing patents and scientific publications relevant to the API class and formulation could invalidate or limit the patent if they disclose similar compositions or methods before the filing date.
3. What strategies can extend the patent's market life?
Applying for SPCs in Europe, developing new formulations, or claiming additional methods of use can prolong patent protection beyond the original term.
4. How does patent landscape influence R&D decisions?
A crowded landscape suggests potential for licensing or partnerships but also indicates significant competition. Narrow claims highlight the necessity of innovation and differentiation.
5. Is there potential for global patent protection?
Yes. By filing PCT applications and entering regional patent offices, the rights can be extended beyond Cyprus, covering key markets like Europe, the US, and Asia.
References
[1] European Patent Office. (2022). Patent data and analysis tools. Retrieved from https://worldwide.espacenet.com/
[2] World Intellectual Property Organization. (2022). Patent Statistics. https://www.wipo.int/portal/en/
[3] European Patent Office. (2023). Guidelines for Examination. https://www.epo.org/laws-practice/legal-texts/guidelines.html
